TELETRADER News
9/3, 7:29 AM (Source: TeleTrader)
more TeleTrader news

Sanofi, GSK start human trials of COVID-19 vaccine

Sanofi SA and GlaxoSmithKline (GSK) announced on Thursday the start of human trials of their candidate vaccine against the coronavirus, based on the recombinant protein-based technology used against seasonal influenza, as it enters the phase 1/2 of its development.

"The initiation of our clinical study is an important step and brings us closer to a potential vaccine which could help defeat COVID-19. Our dedicated teams and partner continue to work around the clock as we aim to deliver the first results in early December. Positive data will enable a prompt start of the pivotal phase 3 trial by the end of this year," Sanofi's Executive Vice President and Global Head Thomas Triomphe said.

Earlier this week, the French pharmaceutical company revealed it is halting its Phase 3 trial of rheumatoid arthritis drug Kevzara as a potential treatment for COVID-19 as it did not provide significant results.

Breaking the News / JR